Figure 4.

sCD163 is elevated in the urine of patients with active renal vasculitis recruited from an independent cohort and compared with a range of control groups. (A) The data from the inception and validation cohorts (n=465) were combined and compared with healthy controls (n=55) and a diverse disease control group comprising samples from patients in the intensive care unit with sepsis with or without AKI (n=32), AKI without sepsis (n=286), and no AKI or sepsis (n=463), in addition to a nonICU disease control group with (n=30) and without (n=54) nonvasculitic GN. The boxes refer to the fraction of cases with a urine sCD163 level >0.3 ng/mmol (dotted line). (B) sCD163 levels were also measured by ELISA in an independent external validation cohort (n=52). Graph showing comparison of levels found in active renal vasculitis (Act), active extrarenal vasculitis, remission renal vasculitis (Rem), and healthy controls. Data are presented as median sCD163 ng/mmol creatinine with interquartile range. Nonparametric one-way ANOVA (Kruskal-Wallis test) and Dunn’s multiple comparison test were used to test for significance of each group compared with the active renal vasculitis group (***P<0.001).